NOTE: This podcast is an evolving collaboration between human and AI. While we strive for accuracy, AI hosts may misinterpret or oversimplify source material. Always refer to the original published articles for clinical decision-making.

If you find any claims made by the AI hosts to be inaccurate, please let us know. Your feedback directly improves future episodes.

Should thalamic sEEG sampling be standard of care, selectively hypothesis-driven, or research-only?

This first Audio Epilepsy Digest release takes up the February 2026 Brain debate cluster on thalamic stereoEEG and focuses on what actually matters for epileptologists at academic centers: SEEG planning, neuromodulation targeting, safety, ethics, and institutional policy.

In this episode, the hosts examine:

- whether thalamic sampling changes real clinical decision-making

- when thalamic signals may be justified in hypothesis-driven intracranial exploration

- how the argument shifts when neuromodulation planning is part of the goal

- where the current literature reflects expert interpretation more than settled comparative outcomes evidence

This is a source-grounded special episode built from a tightly related editorial-plus-opinions packet, so the goal is not to force false consensus. The takeaway is a practical policy conversation for current practice, with explicit attention to what remains uncertain.

--

## Summary
This special episode of *Audio Epilepsy Digest (AED)* takes up a narrow but consequential controversy from the February 2026 *Brain* thalamic stereoEEG cluster: should thalamic sampling be routine clinical practice, a selectively justified extension of hypothesis-driven exploration, or remain largely research-only?
The discussion focuses on what the debate actually means for SEEG planning, neuromodulation strategy, safety, ethics, and institutional policy in academic epilepsy centers.

## Key Takeaways
- The strongest argument for restraint is not that thalamic recordings are never interesting, but that incremental patient-level clinical benefit remains uncertain in many cases and may not justify routine added sampling.- The strongest argument for selective clinical use is that thalamic signals can become decision-relevant when the pre-implant hypothesis already involves network propagation, neuromodulation targeting, or uncertainty that cortical-only sampling may not resolve.- The pro-neuromodulation position is more intervention-oriented than the stricter research-only framing and treats thalamic sampling as part of a therapeutic planning workflow, not only a localization experiment.- Much of the packet is interpretation and expert argument rather than direct comparative outcomes evidence, so this should be heard as a policy and practice debate, not a settled consensus statement.

## Sources
1. *Brain* 149(2):361. "Should thalamic recording be standard practice or institutional review board-approved research in stereoEEG?"2. *Brain* 149(2):371. "Thalamic stereoEEG evaluation: is it justified in clinical practice?"3. *Brain* 149(2):373. "Thalamic stereo EEG: a clinically justified extension of hypothesis-driven intracranial exploration."4. *Brain* 149(2):375. "Thalamic stereoEEG optimizes neurostimulation therapy."5. *Brain* 149(2):378. "The role of thalamic stereoEEG in epilepsy clinical practice."

## Caveats
- This is mainly a debate packet built from editorial and opinion writing rather than randomized trials or head-to-head outcomes studies.- The packet is strong on coherence, but much of the force of the discussion comes from author framing and interpretation.- The local full-text set came from browser extracts because Oxford PDF endpoints remained blocked under automation.